000046921 000__ 01104cam\a22004335i\4500
000046921 001__ 46921
000046921 003__ SzGeWIPO
000046921 005__ 20230504110544.0
000046921 006__ m\\\\eo\\d\\\\\\\\
000046921 007__ cr bn |||m|||a
000046921 008__ 221017s2022\\\\nyu\\\\\o\\\\\000\0\eng\d
000046921 035__ $$a(OCoLC)1348117222
000046921 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046921 041__ $$aeng
000046921 24500 $$aTRIPs and COVID-19: is an IP waiver (un)necessary?.
000046921 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2022
000046921 300__ $$a1 online resource
000046921 336__ $$atext$$2rdacontent
000046921 337__ $$acomputer$$2rdamedia
000046921 338__ $$aonline resource$$bcr$$2rdacarrier
000046921 4901_ $$aIntellectual Property Quarterly,$$vVolume 1;
000046921 542__ $$fhttps://1.next.westlaw.com/Copyright
000046921 588__ $$aCrossref
000046921 590__ $$aPublished online: 2022
000046921 650_0 $$aIntellectual property.
000046921 650_4 $$aCOVID-19 Pandemic
000046921 650_4 $$aDeveloping countries
000046921 650_0 $$aPublic health.
000046921 650_0 $$aVaccines.
000046921 650_0 $$aPatents.
000046921 650_4 $$aTrade-Related Aspects of Intellectual Property (TRIPS)
000046921 7001_ $$aOwade, Victor,$$eauthor.
000046921 7731_ $$tIntellectual Property Quarterly
000046921 7731_ $$wIPQUA
000046921 830_0 $$aIntellectual Property Quarterly;$$vI.P.Q. 2022, 1, 30-43
000046921 85641 $$uhttps://www.westlaw.com/Document/I8AE84010BABB11EC83A9BAB8BFCB759A/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046921 904__ $$aArticle
000046921 980__ $$aIPQUA